We are looking for early-stage investment that can drive global change in kidney care

Renalyte: Redefining Renal Care Through Physiological Mimicry

The Challenge: A 60-Year-Old Standard For six decades, the fundamental technology behind dialysis has remained largely unchanged. While life-sustaining, intermittent treatment fails to replicate the body’s natural processes, creating significant physiological strain and an immense economic burden on healthcare systems, exceeding $100B annually worldwide.

The Solution: Continuous, Physiological Filtration Renalyte is developing a fully implantable Renal Assist Device (RAD) designed to move beyond the limitations of intermittent dialysis. Our approach focuses on what matters most:

• Mimicking Nature: Providing continuous blood filtration ensuring internal stability for the patient

• Essential Precision: Focusing exclusively on critical physiological filtration to maximize device longevity and clinical outcomes

• Safe-by-Design: Our proprietary technology utilizes a Venous-only integration, intentionally avoiding the high-pressure arterial complications that have historically hindered innovation in this space.

The Business Case: Pragmatic Disruption Renalyte addresses the $100B annual cost  and the global shift toward value-based, home-compatible solutions. By reducing the complications associated with 60-year-old technology, we offer a path toward lower systemic costs and significantly improved patient autonomy.

The Investment Opportunity Led by a veteran team of Israeli MedTech experts, Renalyte is achieving key clinical milestones in the development of a scalable, lower-risk solution for chronic kidney disease. We are now inviting strategic partners and Tier-1 investors to join us in establishing the new standard of renal care.Continuous Care. Clinical Safety. Proven Innovation.